Cat. #151227
Anti-HLADRa [TAL 1B5]
Cat. #: 151227
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Human Leukocyte Antigen DR, alpha subunit
Class: Monoclonal
Application: IHC ; ELISA ; FACS ; IHC ; IF ; RIA ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-HLADRa [TAL 1B5]
- Research fields: Immunology
- Clone: TAL 1B5
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 33 kDa
- Reactivity: Human
- Host: Mouse
- Application: IHC ; ELISA ; FACS ; IHC ; IF ; RIA ; WB
- Description: TAL 1B5 may be used for HLA typing.
- Immunogen: Bristol 8 separated alpha chain preparation
- Isotype: IgG1
- Myeloma used: P3/NS1/1-Ag4.1
Target Details
- Target: Human Leukocyte Antigen DR, alpha subunit
- Molecular weight: 33 kDa
- Target background: Human Leukocyte Antigens are highly polymorphic proteins that are involved in the presentation of antigens to the T-cell receptor. There are two classes of HLA antigens, class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D).
Applications
- Application: IHC ; ELISA ; FACS ; IHC ; IF ; RIA ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Roher et al. 2013. PLoS One. 8(3):e59735. PMID: 23555764.
- Bapineuzumab alters a? composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy.
- Chung et al. 2012. Int J Cancer. 131(3):E227-35. PMID: 22174092.
- Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer.
- van Dongen et al. 2010. Int J Cancer. 127(4):899-909. PMID: 20013807.
- Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.
- Thomas et al. 1988. J Pathol. 154(4):353-63. PMID: 2455029.
- HLA-D region alpha-chain monoclonal antibodies: cross-reaction between an anti-DP alpha-chain antibody and smooth muscle.
- Adams et al. 1983. Immunology. 50(4):613-24. PMID: 6197354.
- Production and characterization of monoclonal antibodies recognizing the alpha-chain subunits of human ia alloantigens.
